Re: Platinum study in Berlin

[Guest guest]

PLATINUM

http://www.ithyroid.com/platinum.htm

Eur J Clin Pharmacol 1994;47(1):1-16

Complexes of metals other than platinum as antitumour agents.

Kopf-Maier P Institut fur Anatomie, Freie Universitat Berlin, Germany.

The earliest reports on the therapeutic use of metals or metal-containing

compounds in cancer and leukemia date from the sixteenth and nineteenth

centuries. They were forgotten until the 1960s, when the anti-tumour

activity of the inorganic complex cis-diammine dichloroplatinum (II)

(cisplatin) was discovered. This led to the development of other types of

non-organic cytostatic drugs. Cisplatin has developed into one of the most

frequently used and most effective cytostatic drugs for the treatment of

solid carcinomas. Numerous other metal compounds containing platinum, other

platinum metals, and even non-platinum metals were then shown to be

effective against tumours in man and experimental tumours in animals. These

compounds comprise main-group metallic compounds of gallium, germanium, tin,

and bismuth, early-transition metal complexes of titanium, vanadium,

niobium, molybdenum, and rhenium, and late-transition metal complexes of

ruthenium, rhodium, iridium, platinum, copper, and gold. Several platnium

complexes and four non-platnium metal antitumour agents have so far entered

early clinical trials. Gallium trinitrate and spirogermanium have already

passed phase II clinical studies and have shown limited cytostatic activity

against certain human carcinomas and lymphomas. The two early-transition

metal complexes budotitane and titanocene dichloride have just reached the

end of phase I clinical trials and have been found to have an unusual

pattern of organ toxicity in man. Titanocene dichloride will soon enter

phase II clinical studies.

Publication Types: Review Review, academic

PMID: 7988618, UI: 95080318

J Endocrinol Invest 1991 Jun;14(6):475-80

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced

thyroid cancer. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D,

Simioni N, Casara D, Zorat P, Fiorentino MV Divisione Oncologia Medica,

U.L.S.S. N. 21, Padova, Italy.

Twenty-two advanced consecutive thyroid cancer patients with varying

histologies were treated with the so called BAP regime which consisted of

bleomycin ( 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv In day

5, and cisplatinum (P) 60 to mg/m2 iv in day 5. Patients with progressive,

symptomatic recurrent or disseminated disease unresponsive to hormonal

and/or isotopic treatment were eligible. Nine patients had an Objective

response: two long-lasting complete and seven partial responses were

observed out of 21 evaluable patients. Stable disease was observed in four

additional patients. The median duration of response was 12 months (range,

6-29). The total series experienced a median survival of 11 months (range, 1

to 57), with 2 patients actually disease free. Several histologic types of

thyroid carcinoma responded, but the best responses were observed in

medullary and anaplastic giant-cell carcinomas. Toxicity was reversible in

all but one patient. Of the patients failing on BAP chemotherapy three

responded to a four drug second line combination containing vincristine,

fluorouracil, BCNU and methotrexate. BAP regime can achieve reasonable

palliation, and probably increases survival,in poor-prognosis thyroid

cancers.

PMID: 1723086, UI: 92129805